Payment overview · 2025
General Payments
$1,406.69
34 reported records · 19 companies
Healthcare provider profile · identity verified
Paul Citrin, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · ZEPHYRHILLS, FL · NPI 1043325582
Verified facts
What the public records show
CMS Open Payments records show Paul Citrin, M.D. received $1,406.69 in general payments during 2025 across 34 reported records.
W. L. Gore & Associates, Inc. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $338.44 | 24.1% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $330.87 | 23.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$114.82 | 8.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $104.23 | 7.4% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $95.21 | 6.8% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $51.77 | 3.7% | 3 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $51.36 | 3.6% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $41.76 | 3.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.67 | 2.8% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $35.52 | 2.5% | 1 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $33.39 | 2.4% | 1 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $28.25 | 2.0% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $27.55 | 2.0% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $22.32 | 1.6% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $21.81 | 1.6% | 1 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $20.41 | 1.4% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $18.01 | 1.3% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $17.63 | 1.2% | 1 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $14.67 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,406.69 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $302.97 | 2 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $174.26 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $156.61 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $104.23 | 4 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $53.67 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $51.36 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $46.84 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $41.76 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOT Normalized: perclot |
Device | Baxter Healthcare | $41.54 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $35.52 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| JOBST RELAX Normalized: jobst relax |
Device | BSN Medical Inc | $33.39 | 1 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| RESTOREFLOW Normalized: restoreflow |
Device | LeMaitre Vascular, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $8.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Cilostazol | Cilostazol | 93 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 36 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,406.69 · 34 records | W. L. Gore & Associates, Inc. | APLIGRAF, AQUACEL AG+ EXTRA, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, CGuard Prime Carotid Stent System, CONCERTOTM, CellerateRX, ENDURANT IIS, EXCLUDER Conformable AAA Endoprosthesis with Active Control, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, HAWKONE, HELI-FX ENDOANCHOR SYSTEM, JOBST RELAX, Kerecis GraftGuide, Kerecis SurgiClose, LYMPHA PRESS OPTIMAL PLUS(US) BT, MIRRAGEN ADVANCED WOUND MATRIX, PCD-51 731A (US) - White, PCD-52 737A (US) White, PERCLOT, PREVELEAK, Penumbra System, Pounce Thrombectomy, RESTOREFLOW, RUBY Coil, Restrata Wound Matrix, TheraGenesis Wound Matrix, Varithena Administration Pack | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error